89bio, Inc.: Business Overview, Financials & Competitive Analysis
89bio, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Acquired clinical-stage biotech with validated FGF21 platform targeting large metabolic disease markets. Advanced clinical pipeline (Phase 3 trials) in high-value therapeutic areas (MASH, metabolic disease) with meaningful unmet medical needs. Acquisition by Roche at significant premium validates technology and market opportunity, though company is now transitioning from independent public entity.
What is 89bio, Inc.'s industry? 89bio, Inc. (89bio.com) operates in Biotechnology. AskCyborg classifies 89bio, Inc. under Biotechnology in its company registry.
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Ph...
Cyborg Score thesis
Acquired clinical-stage biotech with validated FGF21 platform targeting large metabolic disease...
Read the full analyst-debate transcript →Get the Latest 89bio, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report Free89bio, Inc. Overview
Pro stress-test →89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG).
Strategic Profile
Pro stress-test →Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company agreed to be acquired by Roche at a price of $14.50 per share in cash at closing in September 2025, representing a premium of approximately 79% to 89bio's closing stock price on September 17, 2025.
Competitive Landscape
Pro stress-test →Competing in the FGF21 analog and metabolic disease space against other clinical-stage and late-stage biotech companies developing therapies for MASH and cardiometabolic diseases. Key competitors include other FGF21 programs and GLP-1-based obesity/metabolic therapies in development.
Industry Context
89bio, Inc. operates in Biotechnology.
Key facts
Founded: 2018 · Headquarters: San Francisco, US · Market cap: N/A